Skip to main content
SpringerLink
Log in

Rotavirus Vaccine (RotaTeq®)

  • Adis Drug Profile
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

  • ▲ RotaTeq® is a live, oral, pentavalent human-bovine reassortant rotavirus vaccine approved for use in the prevention of G1–G4 rotavirus gastroenteritis in infants and children.

  • ▲ Rotavirus vaccine demonstrated good immunogenicity in healthy infants.

  • ▲ Three oral doses of rotavirus vaccine had a protective efficacy against G1–G4 rotavirus gastroenteritis of any severity of 74%, and a protective efficacy against severe G1–G4 rotavirus gastroenteritis of 98%, in the randomized, double-blind, placebo-controlled, multicenter REST (Rotavirus Efficacy and Safety Trial) study; the per-protocol efficacy analysis included >4500 infants.

  • ▲ Healthcare resource use was reduced by rotavirus vaccine, with a 94.5% reduction in the incidence of hospitalization or emergency department care because of G1–G4 rotavirus gastroenteritis. This analysis of the REST trial included >57 000 infants.

  • ▲ Rotavirus vaccine did not increase the risk of intussusception within 42 days of any dose, according to an analysis of the REST trial including almost 70 000 infants. Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Proceedings of the Sixth International Rotavirus Symposium; 2004 Jul 7–9; Mexico City [online]. Available from URL: http://www.sabin.org/PDF/rotavirusengweb.pdf [Accessed 2005 Jun 10]

  2. Widdowson M-A, Bresee JS, Gentsch JR, et al. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005 Jan; 21(1): 26–31

    PubMed  Google Scholar 

  3. Centers for Disease Control and Prevention. CDC’s advisory committee recommends new vaccine to prevent rotavirus: media release [online]. Available from URL: http://www.cdc.gov [Accessed 2006 Mar 21]

  4. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004 May 8; 363 (9420): 1547–50

    Article  Google Scholar 

  5. Treanor JJ, Clark HF, Pichichero M, et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr Infect Dis J 1995 Apr; 14(4): 301–7

    Article  PubMed  CAS  Google Scholar 

  6. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003 Oct; 22(10): 914–20

    Article  PubMed  Google Scholar 

  7. Clark HF, Lawley D, Shrager D, et al. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4. Pediatr Infect Dis J 2004 Mar; 23(3): 206–11

    Article  PubMed  Google Scholar 

  8. Ward RL, Bernstein DI, Smith VE, et al. Rotavirus immunoglobulin A responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis 2004 Jun 15; 189(12): 2290–3

    Article  PubMed  Google Scholar 

  9. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004 Feb; 144(2): 184–90

    Article  PubMed  CAS  Google Scholar 

  10. Merck and Co., Inc. RotaTeq® (rotavirus vaccine, live, oral, pentavalent): prescribing information [online]. Available from URL: http://www.merck.com [Accessed 2006 Mar 21]

  11. Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005 Sep 1; 192Suppl. 1: S17–21

    Article  PubMed  Google Scholar 

  12. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005 Jan–Feb; 15(1): 29–56

    Article  PubMed  Google Scholar 

  13. Merck and Co., Inc. FDA approves Merck’s RotaTeq®, the only vaccine in the U.S. to prevent rotavirus gastroenteritis, a leading cause of severe infant diarrhea; RotaTeq® fits into routine well-baby visit schedule: media release [online]. Available from URL: http://www.merck.com [Accessed 2006 Mar 7]

  14. European Medicines Agency. Initial marketing authorisation applications: media release [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 May 1]

  15. GlaxoSmithKline. Rotarix™: first vaccine against rotavirus available in Europe. Media release [online]. Available from URL: http://www.gsk.com [Accessed 2006 Mar 8]

  16. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006 Jan 5; 354(1): 23–33

    Article  PubMed  CAS  Google Scholar 

  17. Rodriguez Z, Goveia M, Stek J, et al. Efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine when administered concomitantly with licensed pediatric vaccines [abstract no. LB-20]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–9; San Francisco (CA)

  18. Vesikari T, Clark HF, Offit P, et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine (RotaTeq®) upon safety, efficacy, and immunogenicity in healthy infants [abstract no. 1755]. Pediatr Res 2003 Apr; 53 (4 Suppl. Pt 2): 307A

    Google Scholar 

  19. Goveia MG, Hastings P, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine (RotaTeq®) in premature infants [abstract]. 2006 National Immunization Conference; 2006 Mar 6–9; Atlanta (GA)

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, Pennsylvania, 19067, USA

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M. Rotavirus Vaccine (RotaTeq®). Pediatr-Drugs 8, 197–202 (2006). https://doi.org/10.2165/00148581-200608030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200608030-00008

Keywords

Search

Navigation